Citigroup Upgrades Silk Road Medical to Neutral
Citigroup analyst Joanne Wuensch upgrades Silk Road Medical (NASDAQ:SILK) from Sell to Neutral.
Wolfe Research Downgrades Silk Road Medical to Peer Perform
Wolfe Research analyst Mike Polark downgrades Silk Road Medical (NASDAQ:SILK) from Outperform to Peer Perform.
Earnings Scheduled For November 8, 2022
Companies Reporting Before The Bell
• Adtran (NASDAQ:ADTN) is likely to report quarterly earnings at $0.18 per share on revenue of $330.39 million.
Silk Road Medical Priced ~2.32M Share Offering @$43/Share
Silk Road Medical, Inc. (Nasdaq: SILK) today announced the pricing of an underwritten public offering of 2,325,582 shares of its common stock at a public offering price of $43.00 per share, before deducting underwriting discounts and commissions.
Silk Road Medical Late Monday Issued Q3 Revenue Guidance Of $37.4M Vs $33.5M Est.
The company's financial statements as of and for the three months ended September 30, 2022, are not yet available. Accordingly, the information presented below reflects the company's estimates and expectations for the three months ended September 30, 2022, subject to the completion of its financial close process.
Silk Road Medical Announces Proposed Public Offering Of $100M Of Shares Of Common Stock
Silk Road Medical, Inc.
Important Biotech Catalysts For September 7, 2022 – End Of The Day Summary
The U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to Pfizer’s (NYSE:PFE) lead drug GBS6…
Silk Road Medical’s Q2 Margins Hit By Manufacturing Expansion Costs
Silk Road Medical Inc (NASDAQ:SILK) posted Q2 revenue of $33.2 million, an increase of 25% Y/Y, driven primarily by increased…
Earnings Preview: Silk Road Medical
Silk Road Medical (NASDAQ:SILK) is set to give its latest quarterly earnings report on Tuesday, 2022-07-26. Here's what investors need to know before the announcement.
Analysts estimate that Silk Road Medical will report an earnings per share (EPS) of $-0.46.
